 Michael Burgess, MD, PhD
|
| Title(s) | Assistant Clinical Professor, Medicine |
|---|
| School | School of Medicine |
|---|
| vCard | Download vCard |
|---|
|
|
 Biography | University of California, San Francisco | Fellowship | 2012 | Hematology and Medical Oncology | | University of California, San Francisco | Residency | 2009 | Internal Medicine | | David Geffen School of Medicine at UCLA | M.D. | 2007 | Medicine | | University of California, Los Angeles | Ph.D. | 2005 | Molecular Biology | | University of California, Berkeley | B.A. | 1997 | Molecular and Cell Biology |
Overview Bibliographic
-
An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 Jun 14; 131(24):2682-2697. PMID: 29592892.
-
Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell. 2017 02 23; 168(5):817-829.e15. PMID: 28215705.
-
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313. PMID: 28191887.
-
Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015 Jul 20; 4. PMID: 26193121; PMCID: PMC4569895.
-
Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55. PMID: 25361812; PMCID: PMC4271180.
-
Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL. MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14876-81. PMID: 25271328.
-
Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 03; 6(304):ra105. PMID: 24300897; PMCID: PMC4117477.
-
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19466-71. PMID: 17164333.
-
Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006 Aug 11; 6:918-30. PMID: 16906325.
-
Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005 Mar 01; 102(9):3395-400. PMID: 15705718; PMCID: PMC552942.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|